Aldeyra Therapeutics released an updated corporate overview disclosing standardized treatment estimates for reproxalap dry eye disease trials and FDA positions on primary endpoints following a Complete Response Letter.
Key takeaways
Released Corporate Overview on May 1, 2026, with reproxalap efficacy data and FDA endpoint positions.
Received FDA Complete Response Letter citing lack of substantial evidence for reproxalap in dry eye disease.
No plans for additional reproxalap clinical trials; no manufacturing or safety issues identified.
Cash of $70.0M as of December 31, 2026, expected to fund operations into 2028.
Pipeline includes reproxalap (dry eye, allergic conjunctivitis), ADX-248, ADX-246, and ADX-2191 in various immune-mediated indications.